MLEC

Across TCGA pan-cancer cohorts, MLEC mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MLEC data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MLEC mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MLEC expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where MLEC mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.906	1.000	.006	32	view →
LUAD	OS	Tertile	II,III,IV	0.934	0.569	.011	17	view →
PDAC	DFS	Median	IV	0.752	0.348	.048	3	view →
CCRCC	OS	Median	II,III,IV	0.417	0.861	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MLEC–HNSC (DFS)

Open the HNSC breakdown →